| Zicom Group Limited (ZGL) ORDINARY FULLY PAID |
Industrials |
$26 |
Final Director's Interest Notice
|
20 Nov 2025 10:15AM |
$0.140 |
$0.120 |
fallen by
14.29%
|
|
| Investment Austasia Limited (IAL) ORDINARY FULLY PAID |
Industrials |
- |
mFund - Fund Profile - IAL08
|
20 Nov 2025 10:14AM |
n/a |
n/a |
n/a
|
|
| Investment Austasia Limited (IAL) ORDINARY FULLY PAID |
Industrials |
- |
mFund - Fund Profile - IAL05
|
20 Nov 2025 10:14AM |
n/a |
n/a |
n/a
|
|
| Archer Materials Limited (AXE) ORDINARY FULLY PAID |
Information Technology |
$60 |
AGM Presentation
|
20 Nov 2025 10:14AM |
$0.370 |
$0.215 |
fallen by
41.89%
|
|
| Emyria Limited (EMD) ORDINARY FULLY PAID |
Health Care |
$35 |
Proposed issue of securities - EMD
|
20 Nov 2025 10:14AM |
$0.066 |
$0.044 |
fallen by
33.33%
|
|
| Emyria Limited (EMD) ORDINARY FULLY PAID |
Health Care |
$35 |
Institutional Placement Accelerates EMD National Expansion
|
20 Nov 2025 10:13AM |
$0.066 |
$0.044 |
fallen by
33.33%
|
|
EMD - Price-sensitive ASX Announcement
Full Release
Key Points
- Emyria Limited completed an $8 million institutional placement.
- Funds to accelerate national expansion of Empax Clinics.
- First Victorian Empax Clinic to be established at Avive Health’s Mornington site.
- Department of Veterans’ Affairs funds medication-assisted psychotherapy.
- Dual reimbursement pathways established with Medibank and DVA.
- Capital-light model ensures efficient expansion with no significant upfront costs.
- Plan supports community-based treatment programs for veterans and workers.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Webjet Group Limited (WJL) ORDINARY FULLY PAID |
Consumer Discretionary |
$155 |
Change in substantial holding
|
20 Nov 2025 10:13AM |
$0.870 |
$0.395 |
fallen by
54.60%
|
|
| LTR Pharma Ltd (LTP) ORDINARY FULLY PAID |
Health Care |
$89 |
Notification regarding unquoted securities - LTP
|
20 Nov 2025 10:13AM |
$0.450 |
$0.490 |
risen by
8.89%
|
|
| Investment Austasia Limited (IAL) ORDINARY FULLY PAID |
Industrials |
- |
mFund - Fund Profile - IAL02
|
20 Nov 2025 10:12AM |
n/a |
n/a |
n/a
|
|
| Archer Materials Limited (AXE) ORDINARY FULLY PAID |
Information Technology |
$60 |
Chair's 2025 AGM address
|
20 Nov 2025 10:12AM |
$0.370 |
$0.215 |
fallen by
41.89%
|
|
| Ausmon Resources Limited (AOA) ORDINARY FULLY PAID |
Materials |
$2 |
Rare earth elements laboratory results from samples in SA
|
20 Nov 2025 10:12AM |
$0.003 |
$0.002 |
fallen by
50%
|
|
AOA - Price-sensitive ASX Announcement
Full Release
Key Points
- Laboratory assay results received for rare earth elements at Jabuk Prospect.
- September 2025 Aircore Drilling program covered 418 meters with 23 drill holes.
- 24 samples showed elevated REE readings between 130 ppm to 753 ppm.
- Further exploration planned with grid-based vertical aircore drilling over 10 km2.
- Community consultations and access agreements are required for land exploration.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ReadCloud Limited (RCL) ORDINARY FULLY PAID |
Information Technology |
$9 |
FY25 Full Year Results Release
|
20 Nov 2025 10:07AM |
$0.110 |
$0.061 |
fallen by
44.55%
|
|
RCL - Price-sensitive ASX Announcement
Full Release
Key Points
- 109% increase in Underlying EBITDA
- 26% organic growth in VET-in-Schools revenue to $5.7 million
- 17% growth in direct eBook sales to Australian Schools
- Total revenue of $12.9 million, up 5%
- Positive cash flow with $1.9 million cash at 30 September
- Strategic focus on school-facing operations for sustained growth
- Southern Solutions under review due to revenue headwinds
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Shriro Holdings Limited (SHM) ORDINARY FULLY PAID |
Consumer Discretionary |
$49 |
Becoming a substantial holder
|
20 Nov 2025 10:07AM |
$0.790 |
$0.760 |
fallen by
3.80%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$7 |
HITIQ Launches PROTEQT North American Market Strategy
|
20 Nov 2025 10:07AM |
$0.020 |
$0.008 |
fallen by
60%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- PROTEQTâ„¢ North American Launch with a dual-channel approach.
- Rick Shultz appointed as the exclusive Canadian distributor.
- Canada has over 600,000 registered hockey players.
- Immediate commercial momentum with founding order.
- Pilot program deployed at elite-level hockey.
- Production capacity planned for 100,000 units in 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| LTR Pharma Ltd (LTP) ORDINARY FULLY PAID |
Health Care |
$89 |
Notification regarding unquoted securities - LTP
|
20 Nov 2025 10:06AM |
$0.450 |
$0.490 |
risen by
8.89%
|
|
| MaxiPARTS Limited (MXI) ORDINARY FULLY PAID |
Industrials |
$83 |
Chair's Address to Shareholders
|
20 Nov 2025 10:02AM |
$2.400 |
$1.500 |
fallen by
37.50%
|
|
| ReadCloud Limited (RCL) ORDINARY FULLY PAID |
Information Technology |
$9 |
FY25 Full Year Results Presentation
|
20 Nov 2025 10:02AM |
$0.110 |
$0.061 |
fallen by
44.55%
|
|
RCL - Price-sensitive ASX Announcement
Full Release
Key Points
- Sales and fee revenue up 6% driven by VET-in-Schools and direct eBook sales.
- VET-in-Schools revenue grew by 26% with high customer retention.
- Australian direct eBooks sales increased by 17%.
- Industry training revenue declined by 28%.
- Consolidated gross profit increased by 11%.
- Operating expenses increased by 4%, maintaining cost discipline.
- Underlying EBITDA grew by 109% year-on-year.
- Strategic focus on customer retention and onboarding new schools.
- FY26 priorities include extending earnings momentum and increasing customer value.
- The company maintains a strong cash position and is debt-free.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cyprium Metals Limited (CYM) ORDINARY FULLY PAID |
Materials |
$243 |
Cathode Restart Approved by Cyprium Board
|
20 Nov 2025 10:01AM |
$0.330 |
$0.420 |
risen by
27.27%
|
|
CYM - Price-sensitive ASX Announcement
Full Release
Key Points
- Cathode Restart Approved by Cyprium Board
- Re-leaching of existing heap leach pads
- Refurbishment of SXEW plant
- Expected first cathode production in mid-2026
- Strategic transition from developer to copper producer
- Potential for future growth from open pit and regional ore sources
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| WAM Global Limited (WGB) ORDINARY FULLY PAID |
Financials |
$798 |
Gabrielle Trainor Appendix 3Y
|
20 Nov 2025 10:01AM |
$2.400 |
$2.220 |
fallen by
7.50%
|
|
| Acorn Capital Investment Fund Limited (ACQ) ORDINARY FULLY PAID |
Financials |
$78 |
Annual General Meeting Presentation
|
20 Nov 2025 10:01AM |
$0.885 |
$0.870 |
fallen by
1.69%
|
|
ACQ - Price-sensitive ASX Announcement
Full Release
Key Points
- ACQ declared dividends of 5.5 cents per share for FY25.
- The fund achieved a gross portfolio return of 12.6% per annum since inception.
- ACQ's investment strategy focuses on diversification and strong microcap sector performance.
- The portfolio includes exposure to both listed and unlisted microcap companies.
- ACQ is well-positioned to take advantage of improving conditions in the microcap sector.
- Resolutions included adoption of annual and remuneration reports and re-election of directors.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$173 |
Change of Director's Interest Notice - M Tripp
|
20 Nov 2025 9:59AM |
$0.230 |
$0.165 |
fallen by
28.26%
|
|
| LTR Pharma Ltd (LTP) ORDINARY FULLY PAID |
Health Care |
$89 |
Application for quotation of securities - LTP
|
20 Nov 2025 9:59AM |
$0.450 |
$0.490 |
risen by
8.89%
|
|
| ReadCloud Limited (RCL) ORDINARY FULLY PAID |
Information Technology |
$9 |
Appendix 4E and Annual Report
|
20 Nov 2025 9:59AM |
$0.110 |
$0.061 |
fallen by
44.55%
|
|
RCL - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue of $12.92 million for the year ended 30 September 2025.
- Net loss after tax reduced to $415,898 from the previous year's $1.02 million.
- Major revenue sources include eBook solutions and vocational education and training.
- Significant expenditures include employment costs and publisher fees.
- Total assets valued at $11.58 million, with liabilities at $2.5 million.
- Net assets are approximately $9.08 million.
- Emphasis on strategic initiatives for enhancing shareholder value.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| WAM Global Limited (WGB) ORDINARY FULLY PAID |
Financials |
$798 |
Kate Thorley Appendix 3Y
|
20 Nov 2025 9:59AM |
$2.380 |
$2.220 |
fallen by
6.72%
|
|
| Amplia Therapeutics Limited (ATX) ORDINARY FULLY PAID |
Health Care |
$72 |
Positive Response from US FDA to Amplia's Type D Meeting
|
20 Nov 2025 9:59AM |
$0.115 |
$0.140 |
risen by
21.74%
|
|
ATX - Price-sensitive ASX Announcement
Full Release
Key Points
- Amplia Therapeutics Limited received a positive response from the US FDA during a Type D meeting for their planned Phase 2b/3 trial involving narmafotinib, gemcitabine, and Abraxane for pancreatic cancer.
- The FDA supports the two-dose comparison in the Phase 2b study leading into the pivotal Phase 3 stage.
- The proposed changes will minimally impact the planned timelines for the trial.
- The full trial protocol is set to be prepared for FDA review in the first half of 2026, with the study expected to start in late 2026.
- A Type D meeting is a formal FDA interaction allowing companies to obtain specific regulatory feedback outside the standard review cycle.
- Amplia's primary compound, narmafotinib (AMP945), is a FAK inhibitor used in treating pancreatic cancer.
- The ACCENT trial has shown promising results with narmafotinib, achieving a confirmed response rate of 33%.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.